Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2026-02-12 @ 6:23 PM
Study NCT ID:
NCT01748851
Status:
TERMINATED
Last Update Posted:
2014-11-04
First Post:
2012-12-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013274', 'term': 'Stomach Neoplasms'}], 'ancestors': [{'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C519688', 'term': 'XELOX'}, {'id': 'D000069287', 'term': 'Capecitabine'}, {'id': 'C410216', 'term': 'Folfox protocol'}, {'id': 'D005472', 'term': 'Fluorouracil'}], 'ancestors': [{'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 42}}, 'statusModule': {'whyStopped': 'Poor enrollment of patients', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2012-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-11', 'completionDateStruct': {'date': '2014-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-11-02', 'studyFirstSubmitDate': '2012-12-09', 'studyFirstSubmitQcDate': '2012-12-11', 'lastUpdatePostDateStruct': {'date': '2014-11-04', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-12-13', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression free survival', 'timeFrame': '6 months after treatment'}], 'secondaryOutcomes': [{'measure': 'Response rate', 'timeFrame': 'every 6 weeks up to 6 months'}, {'measure': 'overall survival', 'timeFrame': '3 years later initial study start'}, {'measure': 'performance status (quality of life)', 'timeFrame': 'Every 6 weeks up to 1 year', 'description': 'European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 will be used.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Gastric Carcinoma Stage IV']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced gastric cancer.', 'detailedDescription': 'Quality assurance: Data will be collected, controlled, and monitored at the Korean Clinical Study Group (KCSG) data center.\n\nData will be entered throuGh the E-Case report form (CRF) (Web based data input)\n\nKorean Clinical Study Group (KCSG) data center will do the standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management\n\nSample size assessment to specify the number of participants or participant years was consulted Statistical specialist. And data analysis will be also discuss with him\n\nExpected median progression-free survival(PFS) in Xelox: 6 months total number of events required: 359 197 patients will be needed After 10% of follow-up loss, 219 patients in each arm, a total of 438 patients will be enrolled'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age :older than 20\n2. A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT), or 20 mm or longer in conventional CT (it should be used by a consistent method during the study period). (RECIST v1.1)\n\n \\*but, patients who does not have measureable lesion with metastatic resected M1 lymph node or bone metastasis or ascites could be enrolled.\n3. No prior palliative chemotherapy (relapse 1 year later after end of adjuvant treatment available)\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 -2\n5. The following laboratory test results:\n\n ① absolute neutrophil count (ANC) ≥1,500/micro Liter (uL), Platelet ≥ 100,000/uL,\n\n ② aspartate aminotransferase (AST) ≤ 3 x Upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 3 x ULN , Total bilirubin ≤ 2.0 mg/dL (in case of liver metastasis, 5 x ULN of AST, ALT)\n\n ③ Creatinine ≤ 1.5 mg/dL\n6. A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages.\n\nExclusion Criteria:\n\n1. HER-2 Positive patients\n2. Any other malignancies within the past 2 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri\n3. Subjects who received radiotherapy within 4 weeks prior to randomization\n4. Subjects who have chronic or acute infection need to treatment\n5. Subjects who received major operation within 4 weeks prior to randomization\n6. patients with clinically significant (i.e. active) heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmias, etc) or myocardial infarction within past 12 months.\n7. patient with epilepsy or psychiatric problem including central nervous system(CNS) metastasis.\n8. Subjects who not be able to ingestion or have a malabsorption disorder\n9. peripheral neuropathy accompany with functional loss\n10. Prior history of allergic reaction to study treatment drugs\n11. A patient with history of other clinical trial within 4 weeks\n12. A patient of childbearing potential without being tested for pregnancy at baseline for positive. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.)\n13. subject who is decided by investigator decide exclusion with any other reasons'}, 'identificationModule': {'nctId': 'NCT01748851', 'briefTitle': 'XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)', 'organization': {'class': 'OTHER', 'fullName': 'Dong-A University Hospital'}, 'officialTitle': 'A Phase III Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Capecitabine and Oxaliplatin (XELOX) in Comparison to the Combination Therapy of Fluorouracil/Folinic Acid and Oxaliplatin (FOLFOX) in Patients With AGC', 'orgStudyIdInfo': {'id': 'KCSG ST12-05'}, 'secondaryIdInfos': [{'id': 'ML27924', 'type': 'OTHER_GRANT', 'domain': 'Roche Korea Company'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'XELOX', 'description': 'Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks', 'interventionNames': ['Drug: XELOX']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'FOLFOX', 'description': 'Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks', 'interventionNames': ['Drug: FOLFOX']}], 'interventions': [{'name': 'XELOX', 'type': 'DRUG', 'otherNames': ['Xeloda'], 'description': 'capecitabine 1000mg/m2 bid po D1-D14', 'armGroupLabels': ['XELOX']}, {'name': 'FOLFOX', 'type': 'DRUG', 'otherNames': ['5-FU'], 'description': '5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2', 'armGroupLabels': ['FOLFOX']}]}, 'contactsLocationsModule': {'locations': [{'zip': '602-715', 'city': 'Busan', 'country': 'South Korea', 'facility': 'Dong-A University Hospital', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}], 'overallOfficials': [{'name': 'Sung Yong Oh, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Dong-A University Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Dong-A University Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associate Professor', 'investigatorFullName': 'Sung Yong Oh', 'investigatorAffiliation': 'Dong-A University Hospital'}}}}